A detailed history of Summit Trail Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Summit Trail Advisors, LLC holds 2,509 shares of VRTX stock, worth $1.18 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
2,509
Previous 2,099 19.53%
Holding current value
$1.18 Million
Previous $854,000 22.72%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

BUY
$407.69 - $446.08 $167,152 - $182,892
410 Added 19.53%
2,509 $1.05 Million
Q4 2023

Feb 06, 2024

SELL
$343.0 - $410.68 $89,180 - $106,776
-260 Reduced 11.02%
2,099 $854,000
Q3 2023

Oct 30, 2023

BUY
$338.18 - $362.46 $234,020 - $250,822
692 Added 41.51%
2,359 $820,000
Q2 2023

Jul 25, 2023

BUY
$314.42 - $351.91 $296,812 - $332,203
944 Added 130.57%
1,667 $586,000
Q1 2023

May 04, 2023

BUY
$283.23 - $323.1 $204,775 - $233,601
723 New
723 $227,000
Q1 2019

May 16, 2019

SELL
$163.73 - $194.7 $228,567 - $271,801
-1,396 Closed
0 $0
Q4 2018

Feb 13, 2019

SELL
$151.91 - $192.21 $257,487 - $325,795
-1,695 Reduced 54.84%
1,396 $231,000
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $45,958 - $52,810
274 Added 9.73%
3,091 $596,000
Q2 2018

Aug 10, 2018

SELL
$145.72 - $169.96 $948,928 - $1.11 Million
-6,512 Reduced 69.8%
2,817 $479,000
Q1 2018

May 22, 2018

SELL
$151.6 - $177.13 $144 Million - $168 Million
-946,738 Reduced 99.02%
9,329 $956,000
Q1 2018

May 21, 2018

BUY
$151.6 - $177.13 $144 Million - $168 Million
947,878 Added 11575.02%
956,067 $956,000
Q4 2017

Feb 14, 2018

BUY
$137.28 - $155.55 $1.12 Million - $1.27 Million
8,189
8,189 $1.34 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Summit Trail Advisors, LLC Portfolio

Follow Summit Trail Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Trail Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Summit Trail Advisors, LLC with notifications on news.